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Patients and methods:We carried out a cohort study of 704 consecutive HIV-negative, HCV-positive patients with in-
dolent NHL diagnosed and treated from 1993 to 2009 in 39 centers of the Fondazione Italiana Linfomi; 134 patients were
managed with AT for lymphoma control.
Results: For entire cohort, 5-year overall survival (OS) was 78% [95% conﬁdence interval (CI): 74%–82%] and 5-year
progression-free survival (PFS) was 48% (95% CI: 44%–53%). In multivariate analysis, the use of AT during the patients’
life had positive impact on OS. Forty-four of the 100 patients treated with ﬁrst-line AT achieved a complete remission (CR)
and 33 a partial response (PR). HCV-RNA clearance was achieved in 80 patients and was related to lymphoma response.
At a median follow-up of 3.6 years, 5-year PFS was 63% (95% CI: 50%–73%). CR + PR rate was 85% with AT as
second-line treatment.
Conclusion: AT produces HCV-RNA clearance and consequent tumor regression in most patients with HCV-related in-
dolent NHL. AT used at any time is associated with improved OS. Consequently, AT can be considered an option for
patients with indolent lymphomas who do not need immediate cytoreductive treatment.
Key words: HCV, indolent lymphoma, antiviral treatment, outcome
introduction
In addition to liver involvement, hepatitis C virus (HCV) infec-
tion has been linked to lymphoproliferative disorders and the
role of HCV infection in lymphomagenesis may be related to
chronic antigenic stimulation of the virus [1].
Several epidemiological studies have been carried out since
the mid-1990s to investigate the link between HCV and non-
Hodgkin’s lymphoma (NHL). Systematic concluded that HCV
prevalence in patients with B-NHL is higher with respect to the
general population [2]. In subtype-speciﬁc analyses, HCV
prevalence was associated with marginal zone lymphoma
(MZL) [odds ratio (OR) = 2.47], diffuse large B-cell lymphoma
(DLBCL) (OR = 2.24), and lymphoplasmacytic lymphoma
(LPL) (OR = 2.57) [3].
Interestingly, Kawamura et al. [4] demonstrated that sustained
virologic response induced by interferon (IFN) therapy protects
against the development of malignant lymphoma in HCV-
infected patients.
The regression of HCV-associated lymphoma with antiviral
treatment (AT) alone is the strongest argument in favor of an
etiological link between lymphoma and infection [5, 6].
In relation to the relatively low number of patients treated
with AT so far, the impact of this approach on the outcome of
indolent lymphomas associated with HCV infection needs to be
conﬁrmed. To this task, a survey (‘HCV-LNH outcome survey’)
was initiated in Italy under the sponsorship of the Fondazione
Italiana Linfomi (FIL) in 2010 to better deﬁne the outcome and
the efﬁcacy of treatments of HCV-positive NHL. Moreover, we
analyzed separately the 134 patients managed with AT as anti-
lymphoma strategy.
methods
study design
In the nationwide database of FIL (before 2012 named Intergruppo Italiano
Linfomi, IIL), we identiﬁed 704 HCV-positive (serology and/or HCV-RNA),
HIV-negative patients affected by indolent NHL diagnosed between 1993
and 2009 in 39 centers members with available information about treatment.
HCV infection is a substantial health problem in Italy and majority of
patients with NHL are evaluated for HCV infection. HCV-positive cases
were 15% of all registered cases with available HCV serology from participat-
ing centers; HCV serology was not available for 19.5% of all diagnosed cases
in the examined period. We included also cases of mantle-cell lymphoma
with an indolent course.
Since 2000, FIL/IIL centers shared homogeneous procedures for lymph-
oma diagnosis, staging, response assessment, and follow-up. Before 2000,
minimal requirements of homogeneity were adopted. A central pathology
review was not formally carried out; however, participating centers are all
characterized by high rate of lymphomas diagnosis and local pathologists
systematically participate in the activities of updating the diagnostic proce-
dures of the FIL. All lymphoma cases are consecutively included and fol-
lowed by centers participating to the FIL.
The database of HCV-positive indolent NHL was analyzed to establish HCV
infection features, distribution of lymphoma categories, clinical presentation,
natural history, therapeutic management, outcome, and prognostic factors.
We also analyzed in detail virological and lymphoma response and
outcome of 134 patients who received AT both as ﬁrst-line (n = 100) and as
second-line (n = 34) anti-lymphoma treatment: all these patients did not
need immediate citoreductive therapy at the start of AT.
Approval for this study, which was based on the use of archival data, was
obtained from the Institutional Review Board. The report was prepared in
accordance with the STROBE statement [7]. Data management and analysis
were carried out in accordance with the ethical guidelines of the FIL and the
tenets of the Declaration of Helsinki of 1964, as revised in 2000. All patients
gave informed consent.
end points and variables
The primary outcome measure was overall survival (OS); secondary end
points were progression-free survival (PFS), complete remission (CR), and
partial remission (PR) rates. OS was taken from diagnosis until death from
any cause; patients who had not died were censored at the date of their last
follow-up visit. PFS was deﬁned as the time from start of treatment until
lymphoma progression or initiation of new treatment, or death [8]. Several
variables were included in the analysis (Table 1; supplementary Table S1,
available at Annals of Oncology online), including the use of AT at any time
during a patient’s life.
For patients analyzed for anti-lymphoma activity of AT, CR was deﬁned
by the complete disappearance of all detectable sites and symptoms; PR was
deﬁned as a more than 50% reduction. Responses different from CR/PR were
deﬁned as stable disease (SD); progressive disease was considered an increase
in the size of more than 25% of previously documented disease or the ap-
pearance of new lesions. Speciﬁc examinations have been carried out for re-
sponse assessment in peculiar clinical presentations (i.e. paraprotein level
when present before AT, endoscopy for gastric MALT lymphoma). For these
patients, OS and PFS were calculated from the start of therapy.
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statistical analysis
Association between categorical variables was tested by using the Pearson χ2
test or the Fisher’s exact test. Difference in the mean values of quantitative
variables between two independent groups was tested by using the t-test for
unpaired data. The Kaplan–Meier product-limit method was used to esti-
mate OS and PFS.
The adjusted association of AT with OS and PFS was estimated by means
of backward stepwise multivariate Cox’s regression models, after checking
for the applicability assumptions. The signiﬁcance value for exclusion was
set at 0.10, but both models were ‘forced’ to keep AT and diagnosis. AT was
analyzed as a time-dependent covariate. Unadjusted and adjusted hazard
ratios (HR) with 95% conﬁdence interval (95% CI) are provided. The limit
of signiﬁcance for all analyses was deﬁned as a P-value of ≤0.05. All compu-
tations were carried out using Stata 12.1 (2007).
results
clinical and virological features
Clinical features of 704 patients with indolent lymphoma asso-
ciated with HCV infection are summarized in Table 1. There
was a prevalence of females and the median age was 66 years;
MZL was the most common subtype. Virological features are
summarized in supplementary Table S1, available at Annals of
Oncology online.
outcome
Alkylators was the ﬁrst-line treatment in 148 patients (21%),
rituximab + alkylators in 49 (7%), CHOP in 106 (15%), R-
CHOP in 77 (11%), other chemotherapy regimens in 56 (8%),
AT in 100 (14%), radiotherapy 21 (3%), surgery in 21 (3%), anti-
biotics in 13 (2%), and watch and wait in 113 (16%).
Three hundred and twenty-four patients experienced lymph-
oma relapse or progression at a median follow-up of 3.5 years
(range 0.5–17). Five hundred and thirty-nine patients are alive
(169 without evidence of disease), with a 5- and 10-year OS of
78% (95% CI: 74%–82%) and 62% (95% CI: 55%–67%), respectively
(Figure 1); 5- and 10-year PFS of 48% (95% CI: 43%–53%)
and 30% (95% CI: 25%–36%), respectively (Figure 2). Causes
of death were: lymphoma 65%, cardiovascular events 12%,
liver disease 9%, infection 6%, other neoplasia 6%, and other
causes 2%.
univariate and multivariate analysis
In univariate analysis, AT showed a signiﬁcant association both
with OS and with PFS (supplementary Table S2, available at
Annals of Oncology online). Furthermore, age >60 years, B
symptoms, ECOG>1, albumin<3.5 g/dl, and increased LDH
were also associated with OS and PFS, while Ann Arbor stage
III–IV, absence of cryoglobulinemia and of symptomatic cryo-
globulinemia, and the presence of cirrhosis were associated only
with OS (supplementary Table S2, available at Annals of
Oncology online).
Despite the multivariate analysis has shown a signiﬁcant asso-
ciation of age>60 years, cirrhosis, cryoglobulinemia, and
albumin<3.5 g/dl with OS, in multivariate analysis, AT retained
a protective effect with OS (Table 2, Figure 3). On the contrary,
the protective effect of AT on PFS was not conﬁrmed after ad-
justment for confounders.
Table 1. Comparison of clinical features of patients who underwent antiviral therapy as anti-lymphoma treatment with respect to those who did not
n % Antiviral therapy as anti-lymphoma treatment Test and P-value
Yes (134) No (570)
n % n %
Male/female 289/415 41/59 57/77 43/57 232/338 41/59 χ2 = 0.2, P = 0.698
Age >60 years 483 69 70 52 413 73 χ2 = 21.5, P < 0.001
Histotypes
Follicular lymphoma 134 19 12 9 122 21 χ2 = 27.7, P < 0.001
MALT MZL 157 22 29 22 128 22
Primary nodal MZL 59 8 13 9 46 8
Splenic MZL 137 20 36 27 101 18
Small lymphocytic lymphoma 37 5 4 3 33 6
Lymphoplasmacytic lymphoma 53 8 10 7 43 8
Indolent mantle-cell lymphoma 30 4 1 1 29 5
Indolent B-cell NHL NOS 97 14 29 22 68 12
Ann Arbor stage III + IV 550 79 116 87 434 77 χ2 = 6.3, P = 0.012
Extranodal disease 271 42 80 60 191 38 χ2 = 21.4, P < 0.001
Liver involvement 53 8 16 12 37 7 χ2 = 3.1, P = 0.080
ECOG 2–3 65 10 6 4 59 11 χ2 = 5.1, P = 0.025
LDH >UNL 164 24 31 24 133 24 χ2 = 0.0, P = 0.921
Albumin< 3,5 mg/dl 100 16 16 13 84 17 χ2 = 1.0, P = 0.308
Counts (n) and percentage frequencies (%) with the Pearson’s χ2 test and the signiﬁcance level (P-value) are reported.
MZL, marginal zone lymphoma; MALT, mucosa-associated lymphoid tissue; NOS, not otherwise speciﬁed; LDH, lactate dehydrogenase; UNL, upper
normal limit.
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anti-lymphoma antiviral treatment
One hundred and thirty-four patients received AT for lymph-
oma control: 100 patients received AT as the ﬁrst-line option,
while 34 patients received AT as second-line treatment following
a previous therapeutic failure. AT consisted of IFN in 47 patients
(plus RBV in 36) and peg-IFN in 87 (plus RBV in 82). The
median age was 60 years (range 23–80 years) with no difference
between patients treated with AT as ﬁrst or second line
(P = 0.07). Histological, virological, and hematological features
of the 134 patients are summarized in Table 3.
ﬁrst-line antiviral treatment: tolerability and activity. Among
100 patients treated with AT as ﬁrst line (33 with IFN and 67
with peg-IFN), 60 were affected by MZL. HCV genotype was 2
in 52 patients and 1 in 37. The median duration of ﬁrst-line AT
was 7 months (range 2–48). Eighty-seven patients completed
the planned AT; 6 patients discontinued due to toxicity, while 7
patients interrupted AT early due to lymphoma progression and
lack of virological response. HCV-RNA clearance was achieved
in 80 patients (80%).
Forty-four (44%) of patients achieved CR and 33 (33%) PR,
with an ORR of 77% (95% CI: 69%–85%); 14 (14%) had SD.
The median response duration was 33 months.
Lymphoma response was related to achievement of HCV-
RNA clearance (P = 0.003) (supplementary Table S3, available
at Annals of Oncology online). Lymphoma response was not
statistically different between patients with MZL and non-MZL
(ORR: 82% versus 70%), whereas it was lower in splenic MZL
with respect to other MZL cases (ORR: 65% versus 92%;
P = 0.02). ORR was 83% in genotype two carriers and 70% in
genotype one carriers (P = 0.3).
At a median follow-up of 3.6 years, 9 patients progressed and
13 experienced lymphoma relapse after initial response to AT,
with a 5-year PFS of 63% (95% CI: 50%–73%) (Figure 3B). Five-
year PFS for patients not treated with AT as ﬁrst line was 45%
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Figure 1. Overall survival (A) and progression-free survival (B) of entire
series of 704 patients with hepatitis C virus-associated indolent lymphoma.
Table 2. Predictive model for OS and PFS derived from
multivariate backward stepwise Cox analysis, considering antiviral
treatment as a time-dependent covariate
HR 95% CI P-value
Overall survival
Antiviral treatment 0.21 0.06–0.73 0.014
Age>60 years 3.89 1.71–8.85 0.001
B symptoms 1.99 0.88–4.51 0.099
Cirrhosis 2.81 1.24–6.35 0.013
Cryoglobulinemia 0.36 0.15–0.88 0.024
Albumin <3.5 g/dl 3.16 1.64–6.09 0.001
Progression-free survival
Antiviral treatment 0.80 0.48–1.33 0.385
Age>60 years 1.43 0.95–2.17 0.089
ECOG>1 1.64 0.93–2.87 0.085
Albumin <3.5 g/dl 1.55 1.00–2.40 0.050
The mutually adjusted hazard ratios (HRs) with the 95% conﬁdence
interval (95% CI) and the signiﬁcance level (P-value) are reported.
HRs are also adjusted for diagnosis.
Volume 25 | No. 7 | July 2014 doi:10.1093/annonc/mdu166 | 
Annals of Oncology original articles
 at CRO
 A
V
IA
N
O
 (CENTRO RIFERIM
ENTO ONCOLOGICO) on August 1, 2014
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
(95% CI: 49%–50%) and was statistically shorter in comparison
to treated patients (HR = 0.56, 95% CI: 0.39–0.80, P = 0.001).
Eighty-nine patients treated with ﬁrst-line AT are alive, with a
5-year OS of 92% (95% CI: 83%–96%) (Figure 3A); only two
patients died for lymphoma. The other causes of death were:
hepatocellular carcinoma (n = 3), infections (n = 2), and cirrho-
sis, herpetic encephalitis, myelodysplastic syndrome, and
suicide (n = 1 for each). Five-year OS for patients not treated
with AT as ﬁrst line was 75% (95% CI: 71%–80%) and was statis-
tically shorter in comparison to treated patients (HR = 0.39,
95% CI: 0.20–0.73, P = 0.004). OS did not differ according to
genotype, lymphoma category and serum levels of albumin,
β2-microglobulin, and LDH. The impact of type of IFN
(adjusted for levels of albumin, β2-microglobulin, and LDH)
remained signiﬁcant also in multivariate analysis (peg-IFN
versus IFN, HR = 0.08, 95% CI: 0.01–0.81, P = 0.03).
second-line antiviral treatment. Nineteen (56%) of the 34
patients treated with second-line AT (14 with IFN and 20 with
peg-IFN) for relapse after a conventional ﬁrst-line therapy
achieved a CR and 10 (29%) a PR, with an ORR of 85% (95%
CI: 73%–97%). HCV clearance was achieved in 22 patients
(67%). The median response duration was 26 months. At a
median follow-up of 4.1 years, four patients progressed and six
experienced lymphoma relapse after initial response to AT, with
a 5-year PFS of 63% (95% CI: 50%–73%).
discussion
To the best of our knowledge, this is the largest multicenter study
focused on the anti-lymphoma efﬁcacy of AT. Indeed, no reported
study included more than 20 cases and related literature consists
of around 100 patients treated with this strategy [9].
The present study shows that anti-lymphoma activity of AT is
associated with viral load clearance and that AT is an active thera-
peutic option in these patients. The use of AT at any time during
the life of these patients seems to be associated with improved
outcome, which enforces the recommendation that AT must be
considered as ﬁrst-line approach for patients with indolent lymph-
omas who do not need immediate conventional treatment.
Major limitations of the present study are related to retro-
spective nature of the observation and the possible selection,
loss-to-follow-up, referral bias of patients treated with AT;
however, despite these aspects, reported cases are consecutively
observed in centers and the decision of using AT is uniformly
applied in all centers. Although PFS results might have been
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Figure 3. Overall survival (A) and progression-free survival (B) of 100
patients treated with AT as the ﬁrst-line anti-lymphoma treatment.
Table 3. Histological, virological, and hematological features of 134
patients with hepatitis C virus-related indolent B-cell lymphoma
treated with antiviral therapy as anti-lymphoma treatment
First-line AT
(100)
Second-line
AT (34)
n % n %
M/F 41/59 41/59 15/19 44/56
Marginal zone lymphoma 60 60 20 59
Splenic 23 23 12 35
Nodal 12 12 2 6
Extranodal of MALT 25 25 6 18
Follicular lymphoma 5 5 7 20
Lymphoplasmacytic lymphoma 7 7 2 6
Mantle-cell lymphoma 0 0 0 0
Small lymphocytic lymphoma 1 1 3 9
Indolent B-cell NHL NOS 27 27 2 6
Ann Arbor stage III–IV 90 90 28 82
Elevated β2-microglobulin 31 53 23 79
Albumin <3.5 g/dl 10 11 6 19
SerumMC 35 35 13 38
HCV genotype
1 37 39 15 50
2 52 55 13 43
3 5 5 2 7
5 1 1 0 0
Cryoglobulinemia 34 34 10 29
Symptomatic cryoglobulinemia 19 56 7 70
Counts (n) and percentage frequencies (%) are reported.
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biased by the retrospective nature of this study, the signiﬁcant
results observed for OS make clinically relevant the present
ﬁndings. Considering the particular nature of this subset of
lymphoma and the objective difﬁculty to perform prospective
trials in signiﬁcantly wide cohort of patients, our data may
impact the standard of care.
It is possible that there are potential confounding factors that
inﬂuence the difference in OS between the AT group and those
who did not have AT, which we did not have data on (for the
multivariate analysis in Table 2). However, the effect was so
large (HR = 0.33), that it is unlikely other important confoun-
ders could explain this size of effect.
About 10 years ago, some reports attested the efﬁcacy of AT
in HCV-related SMZL [5, 10]. A previous study from our group
extended this experience to a cohort of 13 patients with indolent
lymphoma even different from SMZL [6]. Although that study
included a relatively small number of patients, results showed
no signiﬁcant differences within different lymphomas categories
and suggested that lymphoma response to AT was related to
viral load decrease or disappearance.
ORR in the present group of patients who received upfront
AT is similar to that reported in our ﬁrst study (77% versus
74%) [11], with a slightly lower CR rate (44% versus 58%).
Interestingly, this wide study is in line with previous studies
[10–12], suggesting that HCV-RNA clearance is a conditio sine
qua non to attain lymphoma response.
A relevant contribution of the present study regards the dem-
onstration that tumor regression after AT can be obtained in
diverse lymphoma categories. In fact, response rate was not dif-
ferent between MZL and non-MZL.
In the present study, few patients were lymphoma-unrespon-
sive to AT, which could be related to HCV-independent phase
of disease in which antigenic trigger is no longer necessary for
lymphoproliferation, possibly because of additional genomic
events. Although a relation between genotype and lymphoma
response was not observed, genotype 1 carriers seemed to be less
responsive than genotype 2 carriers. For the past decade, only
40%–45% of these patients achieved a sustained virological re-
sponse when treated with peg-IFN/RBV [12]. Although the
direct anti-lymphoma properties of IFN cannot be ruled out
[11], it should be underlined the clear association between the
lymphoma regression and the clearance of HCV. A possible evo-
lution could be the addition of rituximab to the standard
regimen as reported in HCV-associated cryoglobulinemia
patients [13]. Since rituximab alone therapy has also been
shown to induce lymphoma regression in patients with MZL,
the safety and efﬁcacy of combined AT and rituximab in patients
with HCV-related MZL should be examined.
Finally, IFN-free regimens with direct antiviral agents only
[14] could consent the access to AT also for HCV-positive NHL
patients with contraindications to IFN use. In addition, consid-
ering the antiproliferative properties of IFN [11], lymphoma re-
sponse could deﬁnitely demonstrated that lymphoma regression
is strictly linked to the HCV eradication.
Overall, the present study could be considered as a good his-
torical control group for future prospective trials.
Considering the entire series of 704 patients, AT had a posi-
tive prognostic inﬂuence on OS. Interestingly, a study has shown
that HCV-infected patients who obtained a sustained virologic
response following AT had an HR of lymphoma risk signiﬁ-
cantly lower than patients who did not receive AT [4].
Thus, our data, together with Japanese ﬁndings [4], strongly
support the efﬁcacy of AT in indolent NHL associated with
HCV infection. It remains to clarify the beneﬁt of AT after
(immuno)-chemotherapy if AT is not feasible (for instance, in
the case of symptoms and/or high tumor burden).
In conclusion, the present study shows anti-lymphoma activ-
ity of AT in a large series of HCV-infected patients with indo-
lent NHL. Consequently, this strategy could be considered
the ﬁrst-line option for patients with indolent lymphomas
who do not need for immediate conventional treatment. The
observation that AT used at any time during the patients’ life is
associated with improved OS enforces such a therapeutic oppor-
tunity and suggests a relevant advantage of AT in this setting
beyond the objective detection of lymphoma regression.
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Prognostic signiﬁcance of human papillomavirus
in recurrent or metastatic head and neck cancer:
an analysis of Eastern Cooperative Oncology Group trials
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Background: The purpose of this article was to study the association of human papillomavirus (HPV) with clinical out-
comes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Patients and methods: Archival baseline tumor specimens were obtained from patients treated on two clinical trials in
recurrent or metastatic SCCHN: E1395, a phase III trial of cisplatin and paclitaxel versus cisplatin and 5-ﬂuorouracil, and
E3301, a phase II trial of irinotecan and docetaxel. HPV DNAwas detected by in situ hybridization (ISH) with a wide-spec-
trum probe. p16 status was evaluated by immunohistochemistry. Clinical outcomes of interest were objective response,
progression-free survival (PFS) and overall survival (OS).
Results: We analyzed 64 patients for HPV ISH and 65 for p16. Eleven tumors (17%) were HPV+, 12 (18%) were p16+,
whereas 52 (80%) were both HPV− and p16−. The objective response rate was 55% for HPV-positive versus 19% for
HPV-negative (P = 0.022), and 50% for p16-positive versus 19% for p16-negative (P = 0.057). The median survival was
12.9 versus 6.7 months for HPV-positive versus HPV-negative patients (P = 0.014), and 11.9 versus 6.7 months for p16-
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